Holli Dilks on Molecular Profiling

Holli Dilks, PhD
Published: Friday, Jun 12, 2015



Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Clinical trial eligibility is often dependent on molecular status, but determining which patients should undergo molecular profiling and when can be challenging, said Dilks.

The National Comprehensive Cancer Network (NCCN) offers guideline that can help oncologists determine at which stage of disease patients should be profiled.

Reaching out to pharmaceutical partners to find out the eligibility criteria for patients to enroll can also help oncologists determine when molecular profiling is necessary.
 


Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Clinical trial eligibility is often dependent on molecular status, but determining which patients should undergo molecular profiling and when can be challenging, said Dilks.

The National Comprehensive Cancer Network (NCCN) offers guideline that can help oncologists determine at which stage of disease patients should be profiled.

Reaching out to pharmaceutical partners to find out the eligibility criteria for patients to enroll can also help oncologists determine when molecular profiling is necessary.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x